套细胞淋巴瘤的靶向治疗

Targeted therapy of mantle cell lymphoma

套细胞淋巴瘤(MCL)是最令人失望的疾病之一,因其具有侵袭性非霍奇金淋巴瘤(NHL)及惰性 NHL 的不良特征,前者进展迅速,后者难以治愈,且缺乏最佳治疗选择。临床研究证实利妥昔单抗单用或与化疗联合方案治疗 MCL 有效。波替单抗治疗 MCL 也有效,在联合方案中尚需进一步研究。哺乳动物雷帕霉素抑制剂与放射免疫治疗 MCL 代表一种新的治疗方法,值得进一步研究。

Mantle cell lymphoma(MCL)is one of the most frustrating diseases because it exhibits the worst features of both aggressive non-Hodgkin Lymphoma(NHL)and indolent NHL.It develops rapidly like the former,and it is incurable and lacks of better therapeutic options like the latter.Clinical researchs confirm the activity of rituximab as a single agent and combination regimens(R-Chemo)in the treatment of MCL. Bortezomab is also active in treating patients with MCL and requires further study in combination regiments. The usages of mTOR inhibitor and radioimmunotherapy represents a novel therapeutic approaches in the treatment of MCL.It is also deserved to study.